Related Experiment Video

Updated: Jul 21, 2026

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

Osteopontin as a biomarker for ovarian cancer

Robert C Wallach

    JAMA
    |June 22, 2002
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Models of Bone Metastasis
    08:49

    Models of Bone Metastasis

    Published on: September 4, 2012

    Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity
    09:00

    Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity

    Published on: December 31, 2015

    Related Experiment Videos

    Last Updated: Jul 21, 2026

    Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
    12:24

    Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

    Published on: July 17, 2012

    Models of Bone Metastasis
    08:49

    Models of Bone Metastasis

    Published on: September 4, 2012

    Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity
    09:00

    Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity

    Published on: December 31, 2015

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Ultrasound and Histopathologic Correlation of Ovarian Cystadenofibromas: Diagnostic Value of the "Shadow Sign".

    Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2019

    Origin, frequency and clinical significance of glandular cells in liquid-based pap tests from patients posthysterectomy.

    Acta cytologica·2009

    Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004

    COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

    JAMA·2026

    Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology.

    Acta oncologica (Stockholm, Sweden)·2026

    Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti-PD-1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma.

    Immunology·2026

    Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.

    Journal of the National Cancer Institute·2026

    Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States.

    The oncologist·2026

    Integrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer.

    Microbiology spectrum·2026

    Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet?

    Revista espanola de enfermedades digestivas·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us